Acta Medica Europa

Empirical Treatment in Urinary Tract Infections

Liu Huang [1]

[1] Department of Urology, Beaijing Healt Center, Beijing, China

doi: 10.5281/zenodo.10432303

Dear Editor,

Urinary tract infections (UTIs) are among the most frequent bacterial infections, particularly impacting women throughout their lifespan. Empirical antibiotic treatment remains a crucial initial step in managing suspected UTIs, but the ever-evolving landscape of antimicrobial resistance demands constant adaptation and vigilance. Recent studies have highlighted concerning shifts in resistance patterns among causative uropathogens. Previously reliable agents like amoxicillin and trimethoprim-sulfamethoxazole (TMP-SMX) are showing increasing resistance, even in uncomplicated UTIs. This underscores the importance of considering local resistance data and individual patient factors when selecting empirical therapy (1-4).

While fluoroquinolones have historically served as a mainstay for UTI treatment, concerns regarding their adverse effects, particularly on musculoskeletal health, and their contribution to antimicrobial resistance necessitate judicious use. Nitrofurantoin, with its excellent safety profile and relatively low resistance rates, emerges as a valuable option for uncomplicated UTIs, particularly in regions with low fluoroquinolone resistance. However, a one-size-fits-all approach is detrimental. Recognizing the heterogeneity of UTIs, differentiating between uncomplicated and complicated cases becomes paramount. Complicated UTIs, involving structural or functional abnormalities of the urinary tract, often harbor multidrug-resistant pathogens and necessitate broader-spectrum antibiotics, potentially administered intravenously. Beyond initial antibiotics, optimizing empirical treatment entails several considerations. Shortening treatment duration for appropriate cases not only benefits individual patients but also curbs unnecessary antibiotic exposure and reduces the selective pressure for resistance. Additionally, implementing rapid diagnostics and antimicrobial stewardship programs further optimizes resource allocation and promotes judicious antibiotic use (5-7).

In conclusion, navigating the increasingly complex terrain of empirical UTI treatment necessitates a data-driven, nuanced approach. Local resistance patterns, patient factors, and UTI complexity should guide antibiotic selection. While nitrofurantoin and second-generation cephalosporins hold promise for uncomplicated cases, vigilance regarding fluoroquinolone use and judicious consideration of broader-spectrum agents for complicated UTIs remain crucial. Ultimately, a multi-pronged approach embracing rapid diagnostics, antibiotic stewardship, and evidence-based practices is essential in effectively combating UTIs while minimizing the collateral damage of antimicrobial resistance.

REFERENCES

1. Bader MS, Loeb M, Leto D, Brooks AA. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020;132(3):234-250. doi:10.1080/00325481.2019.1680052

2. Ternes B, Wagenlehner FME. Leitliniengerechte Therapie von Harnwegsinfektionen [Guideline-based treatment of urinary tract infections]. Urologe A. 2020;59(5):550-558. doi:10.1007/s00120-020-01174-0

3. Esposito S, Biasucci G, Pasini A, et al. Antibiotic Resistance in Paediatric Febrile Urinary Tract Infections. J Glob Antimicrob Resist. 2022;29:499-506. doi:10.1016/j.jgar.2021.11.003

4. Cortes-Penfield NW, Trautner BW, Jump RLP. Urinary Tract Infection and Asymptomatic Bacteriuria in Older Adults. Infect Dis Clin North Am. 2017;31(4):673-688. doi:10.1016/j.idc.2017.07.002

5. Piñeiro Pérez R, Cilleruelo Ortega MJ, Ares Álvarez J, et al. Recomendaciones sobre el diagnóstico y tratamiento de la infección urinaria [Recommendations on the diagnosis and treatment of urinary tract infection]. An Pediatr (Engl Ed). 2019;90(6):400.e1-400.e9. doi:10.1016/j.anpedi.2019.02.009

6. Bao W, Koro M, Loh GW, Ortiz A. Urinary Tract Infections in Long-term Care: Evaluation of Uropathogens, Antibiotic Susceptibility, and Empiric Treatment. Sr Care Pharm. 2022;37(6):232-243. doi:10.4140/TCP.n.2022.232

7. Peñaranda GE, Suasnabar DF, Foia E, et al. Urinary tract infections in hospitalized patients. Rev Fac Cien Med Univ Nac Cordoba. 2020;77(4):265-271.

Received: 21 December 2023, Accepted: 24 December 2023, Published: 26 December 2023

Corresponding author: Liu Huang. Department of Urology, Beaijing Healt Center, Beijing, China. liu.huang.dr@gmail.com